H.C. Wainwright & Co., LLC, announced its #1 Ranking by transaction volume for the calendar year of 2024, maintaining the Firm’s top position for 11 consecutive years in PlacementTracker's Market ...

H.C. Wainwright has recently reduced Cassava Sciences Inc (SAVA) stock to Neutral rating, as announced on November 26, 2024, according to Finviz. Earlier, on October 8, 2024, H.C. Wainwright had ...

H.C. Wainwright raised the firm’s price target on Akero Therapeutics (AKRO) to $72 from $50 and keeps a Buy rating on the shares after the ...

Humacyte Inc (HUMA) stock saw a modest uptick, ending the day at $4.61 which represents a slight increase of $0.02 or 0.44% from the prior close of $4.59. The stock opened at $4.59 and touched a low ...

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Hold rating on Agenus (AGEN – Research Report). The company’s shares ...

In conclusion, H.C. Wainwright's analyst remains optimistic about Immunocore's prospects, underpinned by the potential of its diverse pipeline and upcoming clinical milestones. With a market ...

Analysts at HC Wainwright boosted their FY2024 earnings estimates for Precigen in a research report issued to clients and investors on Thursday, January 23rd. HC Wainwright analyst S. Ramakanth now ...

Analysts at HC Wainwright increased their FY2024 earnings per share estimates for Sanara MedTech in a research note issued to investors on Thursday, January 23rd. HC Wainwright analyst Y. Chen now ...

H.C. Wainwright lowered the firm’s price target on Jasper Therapeutics (JSPR) to $40 from $60 and keeps a Buy rating on the shares after the company announced initial data from the BEACON study ...

H.C. Wainwright raised the firm’s price target on Sana Biotechnology (SANA) to $11 from $8 and keeps a Buy rating on the shares. The firm increased its probability of sucess for SC451 to 15% ...